Michael J. Landzberg
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Michael J. Landzberg has a total of 23 co-authors. Here are the top co-authors by number of shared publications:
Paul Khairy
Boston Adult Congenital Heart (BACH) Service, Children’s Hospital and Brigham and Women’s Hospital, Boston, USA
2 shared publicationsAlexander R. Opotowsky
Harvard Medical School, Boston, Massachusetts, USA
1 shared publicationAnthony Furlan
Boston Adult Congenital Heart Group, Department of Cardiology, Brigham and Women's Hospital and Children's Hospital, 300 Longwood Avenue, Boston, MA 02115
1 shared publicationCarole Thomas
Boston Adult Congenital Heart Group, Department of Cardiology, Brigham and Women's Hospital and Children's Hospital, 300 Longwood Avenue, Boston, MA 02115
1 shared publicationClare P. O'DOnnell
From the Boston Adult Congenital Heart Service, Brigham and Women's Hospital and Children's Hospital Boston, Harvard Medical School, Boston, Massachusetts
1 shared publicationCurt J. Daniels
The Ohio State University College of Medicine and Nationwide Children's Hospital, Columbus, Ohio, USA
1 shared publication
Latest Publications
- Open Access
- 31 October 2023
- Published by Elsevier in JACC: Advances
- Vol. 2 (9) , 100649
Timely PAH Identification in Adults With Repaired Congenital Heart Disease? The ACHD-QuERI Registry Insights
- 31 October 2023
- Published by Elsevier in JACC: Advances
- Vol. 2 (9) , 100649
Open AccessTimely PAH Identification in Adults With Repaired Congenital Heart Disease? The ACHD-QuERI Registry Insights
- 28 February 2011
- Published by Elsevier in Progress in Cardiovascular Diseases
- Vol. 53 (4) , 237-238
Introduction: Adult Congenital Heart Disease
- 28 February 2011
- Published by Elsevier in Progress in Cardiovascular Diseases
- Vol. 53 (4) , 237-238
Introduction: Adult Congenital Heart Disease
- 20 July 2010
- Published by SAGE Publications in World Journal for Pediatric and Congenital Heart Surgery
- Vol. 1 (2) , 175-176
Pregnancy in Patients with Tetralogy of Fallot
- 20 July 2010
- Published by SAGE Publications in World Journal for Pediatric and Congenital Heart Surgery
- Vol. 1 (2) , 175-176
Pregnancy in Patients with Tetralogy of Fallot
- 1 April 2009
- Published by Wolters Kluwer Health in Circulation: Cardiovascular Interventions
- Vol. 2 (2) , 83-84
Not Just Big Kids
- 1 April 2009
- Published by Wolters Kluwer Health in Circulation: Cardiovascular Interventions
- Vol. 2 (2) , 83-84
Not Just Big Kids
- 1 August 2007
- Published by Pulmonary Hypertension Association in Advances in Pulmonary Hypertension
- Vol. 6 (3) , 136-141
Emerging Therapy of Congenital Heart Disease Associated with Pulmonary Hypertension
Pulmonary arterial hypertension associated with congenital heart disease (CHD-PAH), as discussed throughout this issue of Advances in Pulmonary Hypertension, is one of the most commonly occurring causes of significant or severe morbidity and untimely mortality in CHD patients.1 Without surgical therapy, it is suggested that some 30% of CHD patients will develop PAH.2 Early recognition and treatment of CHD is often discussed, therefore, as the most effective preventive treatment measure for patients at risk for pulmonary vascular disease. Epidemiologic estimates of occur-rence of CHD-PAH have targeted approximately 15% of all CHD survivors as having PAH.3
- 1 August 2007
- Published by Pulmonary Hypertension Association in Advances in Pulmonary Hypertension
- Vol. 6 (3) , 136-141
Emerging Therapy of Congenital Heart Disease Associated with Pulmonary Hypertension
Pulmonary arterial hypertension associated with congenital heart disease (CHD-PAH), as discussed throughout this issue of Advances in Pulmonary Hypertension, is one of the most commonly occurring causes of significant or severe morbidity and untimely mortality in CHD patients.1 Without surgical therapy, it is suggested that some 30% of CHD patients will develop PAH.2 Early recognition and treatment of CHD is often discussed, therefore, as the most effective preventive treatment measure for patients at risk for pulmonary vascular disease. Epidemiologic estimates of occur-rence of CHD-PAH have targeted approximately 15% of all CHD survivors as having PAH.3
- Open Access
- 27 March 2007
- Published by Wolters Kluwer Health in Circulation
- Vol. 115 (12) , 1622-1633
Interventional Catheterization in Adult Congenital Heart Disease
I mproved medical and surgical therapies for children with congenital heart disease have resulted in a growing population of patients reaching adulthood. 1,2 Over this same time, the field of interventional cardiology has experienced significant growth, driven by technological improvements and better understanding of the mechanisms and intermediateterm results of individual procedures. Consequently, for adults with uncorrected or previously palliated congenital heart disease, percutaneous therapies have increasing acceptance as reasonable additions, alternatives, and treatments of choice when further surgical or medical intervention is contemplated (Table 1). Currently, interventional cardiology of adult congenital heart disease (ACHD) is a wellestablished field on its own and, programmatically, is a fundamental component of any center providing care for these patients. 3 Although limited safety of interventional procedures for the ACHD population has been suggested in centers without ACHD global care programs, 4 the wide variation in clinical presentation, novelty of cardiovascular pathologies (with similarity to as well as marked differences from both congenital and acquired conditions), and potential for concomitant multiple organ system pathology all contribute to situations atypical for standard adult or pediatric laboratories. These concerns, combined with a desire to centralize data collection to establish outcomes assessments for ACHD patients considered for interventional catheterization, lead to the recommendation that such procedures be performed in centers with ACHD expertise and established care programs. 3 In this article, we review the most commonly performed percutaneous procedures in ACHD, including valvuloplasty, angioplasty, and device closures. We also include discussions concerning complex ACHD patients (Table 2) as well as future directions.
- 27 March 2007
- Published by Wolters Kluwer Health in Circulation
- Vol. 115 (12) , 1622-1633
Open AccessInterventional Catheterization in Adult Congenital Heart Disease
I mproved medical and surgical therapies for children with congenital heart disease have resulted in a growing population of patients reaching adulthood. 1,2 Over this same time, the field of interventional cardiology has experienced significant growth, driven by technological improvements and better understanding of the mechanisms and intermediateterm results of individual procedures. Consequently, for adults with uncorrected or previously palliated congenital heart disease, percutaneous therapies have increasing acceptance as reasonable additions, alternatives, and treatments of choice when further surgical or medical intervention is contemplated (Table 1). Currently, interventional cardiology of adult congenital heart disease (ACHD) is a wellestablished field on its own and, programmatically, is a fundamental component of any center providing care for these patients. 3 Although limited safety of interventional procedures for the ACHD population has been suggested in centers without ACHD global care programs, 4 the wide variation in clinical presentation, novelty of cardiovascular pathologies (with similarity to as well as marked differences from both congenital and acquired conditions), and potential for concomitant multiple organ system pathology all contribute to situations atypical for standard adult or pediatric laboratories. These concerns, combined with a desire to centralize data collection to establish outcomes assessments for ACHD patients considered for interventional catheterization, lead to the recommendation that such procedures be performed in centers with ACHD expertise and established care programs. 3 In this article, we review the most commonly performed percutaneous procedures in ACHD, including valvuloplasty, angioplasty, and device closures. We also include discussions concerning complex ACHD patients (Table 2) as well as future directions.
- 1 March 2007
- Published by Elsevier in Clinics in Chest Medicine
- Vol. 28 (1) , 243-253
Congenital Heart Disease Associated Pulmonary Arterial Hypertension
- 1 March 2007
- Published by Elsevier in Clinics in Chest Medicine
- Vol. 28 (1) , 243-253
Congenital Heart Disease Associated Pulmonary Arterial Hypertension